Journal
INTERNATIONAL JOURNAL OF HYPERTHERMIA
Volume 38, Issue 1, Pages 1111-1125Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02656736.2021.1959658
Keywords
High intensity focused ultrasound; modeling; pelvis; treatment prediction; simulation
Funding
- Philips
- NIHR Research for Patient Benefit programme [PB-PG-0815-20001]
- National Institutes of Health Research (NIHR) [PB-PG-0815-20001] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Tumor treatability was overestimated by 52% of tumor volume, while the difference between predicted and clinical treatability was only 9%. The volume and position of ablated tissues varied with the length of the beam path through tissue.
Background Patient suitability for magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) therapy of pelvic tumors is currently assessed by visual estimation of the proportion of tumor that can be reached by the device's focus (coverage). Since it is important to assess whether enough energy reaches the tumor to achieve ablation, a methodology for estimating the proportion of the tumor that can be ablated (treatability) was developed. Predicted treatability was compared against clinically achieved thermal ablation. Methods MR Dixon sequence images of five patients with recurrent gynecological tumors were acquired during their treatment. Acousto-thermal simulations were performed using k-Wave for three exposure points (the deepest and shallowest reachable focal points within the tumor, identified from tumor coverage analysis, and a point halfway in-between) per patient. Interpolation between the resulting simulated ablated tissue volumes was used to estimate the maximum treatable depth and hence, tumor treatability. Predicted treatability was compared both to predicted tumor coverage and to the clinically treated tumor volume. The intended and simulated volumes and positions of ablated tissues were compared. Results Predicted treatability was less than coverage by 52% (range: 31-78%) of the tumor volume. Predicted and clinical treatability differed by 9% (range: 1-25%) of tumor volume. Ablated tissue volume and position varied with beam path length through tissue. Conclusion Tumor coverage overestimated patient suitability for MRgHIFU therapy. Employing patient-specific simulations improved treatability assessment. Patient treatability assessment using simulations is feasible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available